Amyloidosis

This trial is testing an experimental treatment called FKC289 for people with primary AL amyloidosis that has relapsed or not responded to standard care. FKC289 uses a patient's own immune cells, engineered to recognize and attack the abnormal plasma cells that produce the harmfu…

This phase 3 trial compares an investigational drug called etentamig against a standard combination therapy (daratumumab, cyclophosphamide, bortezomib, and dexamethasone) in people newly diagnosed with AL amyloidosis, a rare disease where abnormal proteins build up in organs. Abo…

This master protocol supports several early-phase studies testing different amyloid-targeting drugs in healthy volunteers and people with Alzheimer's disease. The main goals are to check safety and tolerability, and to see whether these drugs can remove amyloid plaques from the b…

This early-stage trial evaluates the safety and tolerability of an experimental drug called LY4405094 in healthy volunteers and people with Alzheimer's disease. Researchers will measure how much of the drug enters the bloodstream and the fluid around the brain, and in Alzheimer's…

This study tests the long-term safety and tolerability of acoramidis, an oral medication that stabilizes the transthyretin protein, in people newly diagnosed with transthyretin amyloid cardiomyopathy (ATTR-CM), a condition that can lead to heart failure. Participants who complete…

This trial tests whether a mechanical, spring-driven device called FreedomEDGE® can safely and effectively deliver daratumumab, a standard treatment for multiple myeloma and amyloidosis. Currently, nurses give these injections by hand, which can be physically demanding. About 100…

This phase 3 trial compares an experimental CAR-T cell therapy, NXC-201, with a standard drug combination (daratumumab plus CyBorD) in people newly diagnosed with AL amyloidosis, a rare condition where abnormal proteins damage organs. Participants receive either a single infusion…

This study tests whether a special PET-CT scan using a drug called evuzamitide can detect signs of cardiac amyloidosis in people whose standard heart scans were unclear but who have high levels of a blood marker called TAD1. About 25 adults with heart failure or a genetic risk fo…

This study explores whether the electrical signal measured by a pacemaker or defibrillator during implantation can help identify cardiac amyloidosis — a condition where abnormal proteins build up in the heart. Researchers will enroll 242 adults aged 65 and older who already need …

This study tests whether an artificial intelligence (AI) program can help doctors identify a rare heart condition called cardiac amyloidosis on routine echocardiograms. The condition causes protein buildup in the heart muscle, leading to heart failure, and is often missed early o…

This study will test whether a faster type of bone scan (CZT-SPECT) can accurately diagnose transthyretin cardiac amyloidosis, a serious heart condition. Researchers will compare the new scan with the standard method in 200 patients. If it works, it could make diagnosis quicker a…

This study aims to see if a new radioactive dye can detect early signs of a heart condition called amyloidosis in people who carry a TTR gene mutation but have no heart failure symptoms. About 80 adults aged 30-80 will receive an injection of the dye and then have a PET/CT scan t…

This study tests whether a computer model can find signs of a heart condition called cardiac amyloidosis in bone scans that were done for other reasons. Researchers will look back at 57 patients' scans to see if the model can correctly identify those with the disease. If it works…

This study looks for early signs of a heart condition called cardiac amyloidosis in people who have had carpal tunnel surgery on both hands. Researchers will use a special heart scan to check for abnormal protein buildup. The goal is to find the disease earlier so treatment can s…

This study tests a new way to find a hidden heart condition called cardiac amyloidosis in people with atrial fibrillation (AF). Researchers will use AI to analyze EKGs and CT scans to spot early signs of the disease. About 500 adults with AF and certain warning signs will be spli…

This study tests whether a structured 5-week cardiac rehabilitation program can improve exercise ability and quality of life in 40 adults with cardiac amyloidosis. Participants will undergo supervised aerobic and strength training five days a week, with tests before and after the…

This study tests whether increasing the pacemaker's lower rate from 60 to 80 beats per minute improves quality of life and daily function in people with ATTR cardiac amyloidosis. The heart in this condition is stiff and depends on a faster heart rate to pump blood. Thirty-four pa…

This study looks at whether a painless skin scan can measure long-term inflammation in people with Familial Mediterranean Fever (FMF). Researchers will compare these skin measurements with a blood-based inflammation score called the CALLY index. The goal is to better understand o…